Compare Citius Pharmaceuticals Inc (CTXR) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Banco Santander SA — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Banco Santander SA trades at $13.49 (market cap $192.86B). The key difference: Banco Santander SA is far larger — about 14160.1× Citius Pharmaceuticals Inc's market cap, and Banco Santander SA pays a 2.06% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Banco Santander SA for 55 Days on average.
| CTXR | SAN | |
|---|---|---|
Market Cap | $13.62M | $192.86B |
Volume | 132,438 | 10,644,519 |
Sector | Health | Financials |
52-Week High | $1.82 | $15.05 |
52-Week Low | $0.48 | $9.65 |
Typical Hold Time | 17 Days | 55 Days |
Enterprise Value | $3.79M | $360.86B |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
Banco Santander (SAN) trades at $13.48, down 1.32% on the day, amid a bearish technical signal. The stock shows mixed earnings performance, with a Q1 2026 beat but a Q2 2026 miss. Fundamentals are solid with a 26.25% net income margin and a P/E of 13.55, while cash flow trends have weakened significantly. Recent news highlights the completion of the Webster acquisition, expanding U.S. presence.
The outlook is cautiously optimistic given strong profitability and analyst support, but risks include declining cash flows, high debt levels, and economic sensitivity. The stock's current valuation may appeal to value-oriented investors, though near-term volatility is likely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
